Uveitis - Market Insight, Epidemiology and Market Forecast - 2027

Uveitis - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 132
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Jul, 2018
  • SKU: DIMI0072
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

1. Report Introduction 2
2. Uveitis Market Overview at a Glance 12
2.1. Total Market Share Distribution Of Uveitis For 7 MM In 2016 12
2.2. Total Market Share Distribution Of Uveitis For 7 Mmin 2025 12
3. Uveitis: Overview 13
3.1. Classification Of Uveitis 13
3.2. Pathophysiology 15
3.3. Symptoms Of Uveitis 16
3.4. Etiology Of Uveitis 16
3.5. Diagnosis Of Uveitis 17
3.6. Treatment Of Uveitis 18
4. Epidemiology and Patient Population 20
4.1. Key Points 20
4.1.1. Population And Forecast Parameters 21
4.1.2. Prevalent Population of Uveitis in 7MM 22
4.1.3. Region-Wise Prevalent Population Of Uveitis 23
4.1.4. Region-Wise Prevalent Population Of Non-Infectious Uveitis (NIU) 24
4.2. United States 25
4.2.1. Prevalent Population Of Uveitis 25
4.2.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 27
4.3. Germany 28
4.3.1. Prevalent Population Of Uveitis 28
4.3.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 30
4.4. France 31
4.4.1. Prevalent Population Of Uveitis 31
4.4.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 33
4.5. Italy 34
4.5.1. Prevalent Population Of Uveitis 34
4.5.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 36
4.6. Spain 37
4.6.1. Prevalent Population Of Uveitis 37
4.6.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 39
4.7. United Kingdom 40
4.7.1. Prevalent Population Of Uveitis 40
4.7.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 42
4.8. Japan 43
4.8.1. Prevalent Population Of Uveitis 43
4.8.2. Sub-Type Specific Prevalent Population Of Non-Infectious Uveitis (NIU) 45
5. Treatment Algorithm 46
5.1. First Line Of Therapy: Corticosteroids 51
5.2. Second Line Of Therapy: Immunosuppressants 52
5.3. Third Line Of Therapy: Biologics 54
6. Current Unmet Needs of Uveitis 56
7. Marketed Drugs 58
7.1. Durezol 59
7.1.1. Product Description 59
7.1.2. Regulatory Milestones 59
7.1.3. Advantages & Disadvantages 60
7.1.4. Product Profile 60
7.1.5. Safety And Efficacy 61
7.1.6. Side Effects 61
7.1.7. SWOT Analysis 62
7.2. Triesence 63
7.2.1. Product Description 63
7.2.2. Regulatory Milestones 63
7.2.3. Advantages & Disadvantages 63
7.2.4. Product Profile 64
7.2.5. Safety And Efficacy 64
7.2.6. Side Effects 64
7.2.7. SWOT Analysis 65
7.3. Retisert 66
7.3.1. Product Description 66
7.3.2. Regulatory Milestones 66
7.3.3. Advantages & Disadvantages 67
7.3.4. Product Profile 67
7.3.5. Safety 68
7.3.6. Efficacy 68
7.3.7. Side Effects 69
7.3.8. SWOT Analysis 70
7.4. Ozurdex 71
7.4.1. Product Description 71
7.4.2. Regulatory Milestones 71
7.4.3. Advantages & Disadvantages 71
7.4.4. Product Profile 72
7.4.5. Efficacy 72
7.4.6. Safety 73
7.4.7. Side Effects 74
7.4.8. SWOT Analysis 75
7.5. Humira 76
7.5.1. Product Description 76
7.5.2. Regulatory Milestones 76
7.5.3. Advantages & Disadvantages 77
7.5.4. Product Profile 77
7.5.5. Safety And Efficay 77
7.5.6. Side Effects 78
7.5.7. SWOT Analysis 79
8. Emerging Drugs Analysis 80
8.1. Phase III Drugs Analysis- Corticosteroids 80
8.2. Phase III Drugs Analysis-Immunosuppressants 81
8.3. Phase II Drugs Analysis-Biologics 82
8.4. Emerging Drugs: Phase III Therapeutics 83
8.4.1. ADX-102 83
8.4.1.1. Product Description 83
8.4.1.2. Clinical Development 83
8.4.1.3. Advantages & Disadvantages 83
8.4.1.4. Product Profile 84
8.4.1.5. Safety And Efficacy 84
8.4.1.6. Clinical Pipeline Activity 85
8.4.1.7. Ongoing Trials Information 86
8.4.1.8. Clinical Trial By Phase 87
8.4.1.9. SWOT Analysis 88
8.4.2. Durasert 89
8.4.2.1. Product Description 89
8.4.2.2. Clinical Development 89
8.4.2.3. Advantages & Disadvantages 91
8.4.2.4. Product Profile 91
8.4.2.5. Safety And Efficacy 91
8.4.2.6. Side Effects 92
8.4.2.7. Clinical Pipeline Activity 93
8.4.2.8. Ongoing Trials Information 94
8.4.2.9. Clinical Trial By Phase 95
8.4.2.10. SWOT Analysis 96
8.4.3. Sirolimus 97
8.4.3.1. Product Description 97
8.4.3.2. Regulatory Milestones 97
8.4.3.3. Clinical Development 98
8.4.3.4. Advantages & Disadvantages 98
8.4.3.5. Product Profile 98
8.4.3.6. Safety And Efficacy 98
8.4.3.7. Clinical Pipeline Activity 99
8.4.3.8. Ongoing Trials Information 100
8.4.3.9. Clinical Trial By Phase 101
8.4.3.10. SWOT Analysis 102
8.4.4. EGP-437 103
8.4.4.1. Product Descripion 103
8.4.4.2. Regulatory Milestones 103
8.4.4.3. Clinical Development 104
8.4.4.4. Advantages & Disadvantages 104
8.4.4.5. Product Profile 105
8.4.4.6. Safety And Efficacy 105
8.4.4.7. Side Effects 105
8.4.4.8. Clinical Pipeline Activity 106
8.4.4.9. Ongoing Trials Information 107
8.4.4.10. Clinical Trial By Phase 108
8.4.4.11. SWOT Analysis 109
8.5. Emerging Drugs: Phase II Therapeutics 110
8.5.1. Sarilumab 110
8.5.1.1. Product Description 110
8.5.1.2. Product Development Activities 110
8.5.1.3. Clinical Development 110
8.5.1.4. Advantages & Disadvantages 110
8.5.1.5. Product Profile 111
8.5.1.6. Safety And Efficacy 111
8.5.1.7. Clinical Pipeline Activity 112
8.5.1.8. Clinical Trial By Phase 113
9. Market Size of Uveitis in 7MM 114
9.1. 7 Major Market Outlook 114
9.2. Market Size Of Uveitis In 7MM 116
9.3. Region Wisemarket Size Of Uveitis 117
9.3.1. United States 118
9.3.1.1. Market Outlook 118
9.3.1.2. Market Size 119
9.3.2. EU5 120
9.3.2.1. Market Outlook 120
9.3.2.2. Germany Market Size 121
9.3.2.3. France Market Size 122
9.3.2.4. Italy Market Size 123
9.3.2.5. Spain Market Size 124
9.3.2.6. United Kingdommarket Size 125
9.3.3. Japan 126
9.3.3.1. Market Outlook 126
9.3.3.2. Market Size 127
10. Appendix 129
10.1. Report Methodology 129
11. Consulting Services 131
12. Disclaimer 132
13. About DelveInsight 132

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis  (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type  Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type  Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type  Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain  (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type  Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33:  Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU)  in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain  (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and  Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.